Search

This letter to the editor discusses a study on the effects of abrocitinib, a medication used to treat atopic dermatitis, on platelet counts. The study found that abrocitinib treatment resulted in a decrease in platelet counts, with the lowest point occurring at week 4 and gradually returning to normal levels. The higher dose of abrocitinib had a more significant impact on platelet counts. The mechanism behind this effect is not yet understood, and further research is needed to determine the long-term effects and potential risks of abrocitinib treatment. Additionally, the article explores the role of the Ashwell-Morell receptor in regulating the production of thrombopoietin, a protein crucial for platelet production. This research provides valuable insights into platelet production mechanisms and may lead to new treatments for blood clotting disorders. [Extracted from the article]

Introduction: Dupilumab is approved for a variety of type 2 inflammatory diseases. Changes in chemokine levels during treatment require further analysis. Aim: We evaluated changes in eotaxin-3 and PARC levels after dupilumab treatment through a meta-analysis, aiming to provide more comprehensive results. Material and methods: Databases were searched to select eligible publications. The study quality was assessed after inclusion. The standardized mean difference (SMD) was used for evaluation. Results: Four studies were included. Eotaxin-3 levels were not seen significantly decreased at weeks 1 and 12, with SMD = -0.39 (95% CI: -1.78, 0.99) and -2.60 (95% CI: -5.77, 0.57), respectively (p > 0.05). Eotaxin-3 levels decreased significantly at weeks 2, 4, 8, 16, 24, 36, and 52, with SMD = -0.94 (95% CI: -1.61, -0.27); -1.17 (95% CI: -1.49, -0.84); -1.20 (95% CI: -1.52, -0.88); -1.31 (95% CI: -1.83, -0.79); -4.57 (95% CI: -6.90, -2.33); -5.28 (95% CI: -5.52, -5.04); and -4.03 (95% CI: -4.22, -3.85) (p < 0.05), respectively. PARC levels decreased significantly at weeks 4, 8, 12, and 16, with SMD = -1.08 (95% CI: -1.59, -0.58); -1.17 (95% CI: -1.68, -0.66); -1.11 (95% CI: -1.61, -0.60); and -1.15 (95% CI: -1.66, -0.64) (p < 0.05), respectively. Conclusions: Eotaxin-3 and PARC levels can be significantly reduced in patients treated with dupil [ABSTRACT FROM AUTHOR]

A meta-analysis and trial sequential analysis was conducted to evaluate the risk of COVID-19 in patients with atopic dermatitis (AD). Seven studies were included in the analysis, which showed that the risk of COVID-19 in AD patients was similar to that of control subjects. The analysis also suggested that AD patients may have better hygiene habits and reduced social interaction, which could contribute to a lower infection risk. However, the impact of AD on the severity of COVID-19 was not analyzed. It is recommended that AD patients continue to practice prevention measures and consider teledermatology for follow-up visits. [Extracted from the article]

This article is a meta-analysis and trial sequential analysis that evaluates the risk of bone fractures in patients with atopic dermatitis (AD). The study includes four high-quality studies from different regions, with a total of 409,366 AD patients and 1,704,553 control subjects. The analysis shows that AD patients have an elevated risk of bone fractures compared to non-AD control subjects, with a risk ratio of 1.10. The study suggests that clinicians should be aware of the increased fracture risk in AD patients and further research is needed to understand the mechanisms behind this association. [Extracted from the article]